Form 8-K - Current report:
SEC Accession No. 0000078003-26-000053
Filing Date
2026-05-05
Accepted
2026-05-05 07:01:20
Documents
14
Period of Report
2026-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pfe-20260505.htm   iXBRL 8-K 40495
2 EX-99 pfe-3292026xex99.htm EX-99 592535
7 pfizerlogo.jpg GRAPHIC 38679
  Complete submission text file 0000078003-26-000053.txt   914669

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pfe-20260505.xsd EX-101.SCH 3623
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pfe-20260505_def.xml EX-101.DEF 17176
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pfe-20260505_lab.xml EX-101.LAB 31917
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pfe-20260505_pre.xml EX-101.PRE 18083
17 EXTRACTED XBRL INSTANCE DOCUMENT pfe-20260505_htm.xml XML 7164
Mailing Address 66 HUDSON BOULEVARD EAST NEW YORK NY 10001-2192
Business Address 66 HUDSON BOULEVARD EAST NEW YORK NY 10001-2192 2127332323
PFIZER INC (Filer) CIK: 0000078003 (see all company filings)

EIN.: 135315170 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-03619 | Film No.: 26940359
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)